Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SGMO 
Sangamo Therapeutics Inc (SGMO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: SGMO (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $4.1
1 Year Target Price $4.1
| 3 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 54.28% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 192.88M USD | Price to earnings Ratio - | 1Y Target Price 4.1 |
Price to earnings Ratio - | 1Y Target Price 4.1 | ||
Volume (30-day avg) 7 | Beta 1.23 | 52 Weeks Range 0.41 - 3.18 | Updated Date 10/18/2025 |
52 Weeks Range 0.41 - 3.18 | Updated Date 10/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.26 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -77.48% | Operating Margin (TTM) -97.54% |
Management Effectiveness
Return on Assets (TTM) -41.15% | Return on Equity (TTM) -292.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 196313639 | Price to Sales(TTM) 2.36 |
Enterprise Value 196313639 | Price to Sales(TTM) 2.36 | ||
Enterprise Value to Revenue 2.4 | Enterprise Value to EBITDA -1 | Shares Outstanding 301709485 | Shares Floating 294887834 |
Shares Outstanding 301709485 | Shares Floating 294887834 | ||
Percent Insiders 2.2 | Percent Institutions 17.1 |
Upturn AI SWOT
Sangamo Therapeutics Inc
Company Overview
History and Background
Sangamo Therapeutics, Inc. was founded in 1995. It's a genomic medicine company focused on translating ground-breaking science into genomic therapies that transform patientsu2019 lives using gene editing, gene therapy, and cell therapy.
Core Business Areas
- Gene Editing: Developing therapies using Zinc Finger Nucleases (ZFNs) to precisely edit disease-causing genes. Their lead programs are focused on in vivo gene editing for monogenic diseases.
- Cell Therapy: Developing ex vivo cell therapies, including engineered cell therapies for immuno-oncology.
- Gene Therapy: Gene therapy uses viral vectors, like adeno-associated viruses (AAVs), to deliver a functional copy of a gene to cells to compensate for a non-functional gene or to introduce a novel or improved function.
Leadership and Structure
Sangamo is led by Sandy Macrae, CEO. The company has a typical biotech organizational structure with departments for R&D, clinical development, manufacturing, and commercial operations. A Board of Directors provides oversight.
Top Products and Market Share
Key Offerings
- Giroctocogene Fitelparvovec (SB-525): A gene therapy candidate for hemophilia A developed with Pfizer. The phase 3 AFFINE study aims to deliver a functional gene to produce Factor VIII. Competitors include BioMarin's Valrox, CSL Behring, and Roche. Sangamo's revenue is contingent on milestones and royalties.
- ST-920: An AAV-based gene therapy for Fabry disease. It aims to deliver a functional GLA gene to produce the alpha-galactosidase A enzyme. Competitors include Amicus Therapeutics' Galafold and enzyme replacement therapies (ERTs) from Takeda (Replagal) and Sanofi (Fabrazyme). Sangamo's revenue is contingent on milestones and royalties.
Market Dynamics
Industry Overview
The genomic medicine industry is experiencing rapid growth, fueled by advancements in gene editing, gene therapy, and cell therapy technologies. There is significant investment and increasing regulatory acceptance. High unmet medical needs for genetic disorders drive demand.
Positioning
Sangamo is positioned as a pioneer in gene editing using ZFN technology, but faces increasing competition from CRISPR-based gene editing companies. They have strategic partnerships with larger pharmaceutical companies.
Total Addressable Market (TAM)
The total addressable market for genomic medicines is projected to reach hundreds of billions of dollars in the coming years. Sangamo, with its diverse pipeline and partnerships, aims to capture a significant share of this market. The exact size is difficult to determine as it depends on clinical success and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Pioneering ZFN gene editing technology
- Strategic partnerships with major pharmaceutical companies
- Diverse pipeline of gene editing and gene therapy programs
- Strong intellectual property portfolio
Weaknesses
- ZFN technology is less widely adopted compared to CRISPR
- High R&D costs and long development timelines
- Dependence on partnerships for funding and commercialization
- Clinical trial risks and regulatory hurdles
Opportunities
- Expanding into new therapeutic areas with gene editing and gene therapy
- Developing next-generation gene editing technologies
- Securing regulatory approvals for lead programs
- Growing demand for personalized medicine and gene-based therapies
Threats
- Competition from CRISPR-based gene editing companies
- Adverse events or safety concerns in clinical trials
- Changes in regulatory landscape or reimbursement policies
- Failure of clinical trials
Competitors and Market Share
Key Competitors
- CRSP
- EDIT
- BEAM
Competitive Landscape
Sangamo faces strong competition in the gene editing space from companies like CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), and Beam Therapeutics (BEAM). CRISPR-based technologies are more widely adopted, but Sangamo has established partnerships and a diverse pipeline.
Growth Trajectory and Initiatives
Historical Growth: Growth is characterized by fluctuations due to partnership agreements and milestones. Data above in Financial Performance.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and continued expansion of the pipeline. Analyst estimates vary widely.
Recent Initiatives: Focus on advancing lead programs in hemophilia A and Fabry disease, expanding partnerships, and developing next-generation gene editing technologies.
Summary
Sangamo Therapeutics is a pioneer in gene editing but faces increasing competition. Its partnerships are a strength, but clinical trial success is crucial for future growth. ZFN technology is less popular than CRISPR, posing a challenge. It needs to drive its lead programs through regulatory approval and secure new partnerships to solidify its market position and financial sustainability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Industry news and publications
- Company press releases
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share numbers are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sangamo Therapeutics Inc
Exchange NASDAQ | Headquaters Richmond, CA, United States | ||
IPO Launch date 2000-04-06 | CEO, President & Director Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 183 | Website https://www.sangamo.com |
Full time employees 183 | Website https://www.sangamo.com | ||
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.